Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameEthk Labs Inc.
Stock Code01931
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們為中國體外診斷(IVD)產品分銷商,主要透過達承於上海分銷IVD分析儀、試劑及其他耗材,並從事自有品牌IVD產品的研究、開發、生產及銷售。
Listing Date2019-07-12
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)上海市浦東新區張江高科技園區畢昇路299弄第一上海中心6號樓602室
Business Address (Hong Kong)香港沙田安平街8號偉達中心1703室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.ivdholding.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 3.07 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2019-06-29 to 2019-07-05
Global Offering Shares333,400,000 shares
HK Public Offer Shares (Initial)33,340,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)300,060,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,333,400,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,023,538,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 1.29B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +627%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status年內溢利約人民幣99.5百萬元
Period-End Cash Balance人民幣115.4百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201620172018
Revenue 1,380,8701,595,6261,852,514
Cost of sales -1,050,586-1,235,209-1,484,574
Gross profit 330,284360,417367,940
Other income and gains, net 9,0765,89127,273
Selling and distribution expenses -103,838-80,178-80,971
Administrative expenses -29,710-32,821-37,495
Net finance costs -7,254-7,732-6,633
Share of associates and JVs -462-259-344
Profit before tax 193,076240,798265,803
Income tax expense -54,252-66,718-73,642
Profit for the year 138,824174,080192,161
Balance Sheet
Item 201620172018
Cash and cash equivalents 156,790220,802163,678
Trade and bills receivables 107,052137,828190,908
Inventories 422,796473,590525,823
Total current assets 890,2651,069,2391,085,185
Total current liabilities 397,538424,384274,483
Total equity 492,116637,374792,382
Interest-bearing borrowings 130,000100,00040,000
Cash Flow Statement
Item 201620172018
Net cash from operating activities -13,42668,51466,733
Net cash from investing activities 3,0639,0289,059
Net cash from financing activities 27,855-12,115-133,568
Net increase in cash 17,49265,427-57,776
Depreciation of PP&E 8,4927,5147,064
Purchase of PP&E -1,773-351-721
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 3.07
First Day OpenHK$ 2.81
First Day Change-71.34%
First Day Volume38324000.0
First Day Turnover118896000.0
Use of Proceeds
1、約49.6%或461.7百萬港元將用于結清收購威士達60%股權的現金代價之未償還結余; 2、約32.9%或306.8百萬港元將用于根據股東協議向本公司及威士達現有股東支付部分特別股息; 3、約6.8%或63.7百萬港元將主要用于擴大分銷業務項下的客戶群; 4、約3.5%或32.5百萬港元將用于繼續研發我們的自有品牌產品; 5、約2.6%或24.0百萬港元將用于擴展我們的分銷業務及改善我們的分銷價值鏈; 6、約4.6%或43.0百萬港元將用于營運資金及一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)
中银国际亚洲有限公司 CE AET863
Overall Coordinators (1)
中银国际亚洲有限公司 CE AET863
Joint Bookrunners (4)
中银国际亚洲有限公司 CE AET863 oOo Securities (HK) Group Limited CE AJH488 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 海通国际证券有限公司 CE AAF806
Joint Lead Managers (4)
中银国际亚洲有限公司 CE AET863 oOo Securities (HK) Group Limited CE AJH488 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 海通国际证券有限公司 CE AAF806

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman何鞠誠—
Company Secretary林惠茵—
No director data available.

Major Shareholders

Major Shareholders & Holdings何鞠誠、梁景新及林賢雅連同彼等各自全資投資控股公司合共持有約34.78%股份;新華醫療透過全資附屬公司華佗持有約33.27%股份。
About this page

This page shows Ethk Labs Inc. (01931) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect